Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Phase 2

Terminated

• Conditions: Cystitis, Interstitial

• Registration Number: NCT00380783
• Lead Sponsor: Allergan

Brief Summary

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-09-22
• Study First Submitted QC: 2006-09-22
• Study First Posted: 2006-09-26
• Study Start: 2006-10
• Primary Completion: 2007-03
• Study Completion: 2007-03
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-27
• Last Update Posted: 2011-05-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 2

Inclusion Criteria

• Diagnosis of painful bladder syndrome/interstitial cystitis
• Moderate or severe bladder pain

Exclusion Criteria

• Any other uncontrolled disease
• Pregnant or nursing females

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Reduction in daily pain scores